Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free WHWK Stock Alerts

Whitehawk Therapeutics (WHWK) Financials

Whitehawk Therapeutics logo
$3.90 -0.07 (-1.76%)
As of 10:21 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Whitehawk Therapeutics

Annual Income Statements for Whitehawk Therapeutics

This table shows Whitehawk Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -0.03 -21 -22 -10 -23 -4.47 -111 -61 -66 -64 -21
Consolidated Net Income / (Loss)		 -0.03 -17 -21 -10 -23 -3.48 -110 -61 -66 -64 -21
Net Income / (Loss) Continuing Operations		 -0.03 -17 -21 -10 -23 -3.48 -110 -61 -66 -64 -21
Total Pre-Tax Income 		-0.03 -17 -21 -10 -23 -3.48 -110 -61 -66 -64 -21
Total Operating Income		 -0.02 -17 -21 -11 -24 -2.55 -111 -63 -72 -67 -114
Total Gross Profit		 0.00 0.00 0.00 20 0.00 15 1.12 14 22 23 6.39
Total Revenue		 0.00 0.00 0.00 20 0.00 15 1.12 15 24 26 7.15
Operating Revenue		 - - - 20 0.00 15 1.12 15 24 26 7.15
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.34 2.81 3.02 0.76
Operating Cost of Revenue		 - - - - - - 0.00 1.34 2.81 3.02 0.76
Total Operating Expenses		 0.02 17 21 31 24 17 112 77 93 90 121
Selling, General & Admin Expense		 0.02 5.27 9.24 13 9.76 2.12 19 40 45 37 30
Research & Development Expense		 - 11 12 18 13 15 20 33 49 51 91
Restructuring Charge		 - - - - 1.86 - - - 0.00 2.64 0.00
Total Other Income / (Expense), net		 -0.01 -0.35 -0.01 0.78 1.17 -0.93 1.13 2.17 6.17 3.77 94
Interest Expense		 0.01 - - - - 0.82 0.47 0.23 0.23 0.15 0.00
Interest & Investment Income		 - -0.48 -0.11 0.78 1.03 0.04 0.01 2.40 6.40 3.93 6.23
Other Income / (Expense), net		 - 0.13 0.09 0.01 0.14 -0.15 1.59 0.00 -0.00 -0.00 88
Income Tax Expense		 - - - - - 0.00 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($0.01) ($24.52) ($1.03) ($0.31) ($0.57) ($1.76) ($12.41) ($2.69) ($2.44) ($2.36) ($0.33)
Weighted Average Basic Shares Outstanding		 5M 852.67K 21.67M 33.93M 40.59M 2.54M 8.92M 22.51M 26.92M 27.03M 61.89M
Diluted Earnings per Share		 ($0.01) ($24.52) ($1.03) ($0.31) ($0.57) ($1.76) ($12.41) ($2.69) ($2.44) ($2.36) ($0.33)
Weighted Average Diluted Shares Outstanding		 5M 852.67K 21.67M 33.93M 40.59M 2.54M 8.92M 22.51M 26.92M 27.03M 61.89M
Weighted Average Basic & Diluted Shares Outstanding		 5M 852.67K 21.67M 33.93M 40.59M 2.54M 8.92M 24.44M 24.55M 46.78M 47.20M

Quarterly Income Statements for Whitehawk Therapeutics

This table shows Whitehawk Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -16 -16 -18 -15 -13 -18 73 -53 -18 -23 -22
Consolidated Net Income / (Loss)		 -16 -16 -18 -15 -13 -18 73 -53 -18 -23 -22
Net Income / (Loss) Continuing Operations		 -16 -16 -18 -15 -13 -18 73 -53 -18 -23 -22
Total Pre-Tax Income 		-16 -16 -18 -15 -13 -18 73 -53 -18 -23 -22
Total Operating Income		 -18 -18 -20 -16 -13 -19 -15 -55 -20 -25 -24
Total Gross Profit		 5.26 5.40 4.70 5.40 6.41 6.45 6.39 0.00 0.00 - 0.00
Total Revenue		 5.96 6.33 5.35 6.18 7.21 7.24 7.15 0.00 0.00 - 0.00
Operating Revenue		 5.96 6.33 5.35 6.18 7.21 7.24 7.15 0.00 0.00 - 0.00
Total Cost of Revenue		 0.70 0.93 0.65 0.78 0.80 0.79 0.76 0.00 0.00 - 0.00
Operating Cost of Revenue		 0.70 0.93 0.65 0.78 0.80 0.79 0.76 0.00 0.00 - 0.00
Total Operating Expenses		 23 23 24 21 20 25 22 55 20 25 24
Selling, General & Admin Expense		 11 10 11 7.89 7.19 11 13 5.94 5.20 5.87 6.29
Research & Development Expense		 12 13 14 13 10.00 14 8.79 49 14 19 17
Total Other Income / (Expense), net		 1.55 1.45 1.22 1.00 0.87 0.68 88 2.13 1.80 1.64 1.33
Interest & Investment Income		 1.61 1.50 1.28 1.06 0.91 0.68 0.79 1.98 1.85 1.61 1.33
Other Income / (Expense), net		 0.00 0.00 -0.00 -0.00 -0.00 - 87 0.16 -0.05 0.03 0.00
Income Tax Expense		 - - - - - - 0.00 - - - 0.00
Basic Earnings per Share		 ($0.60) ($0.60) ($0.68) ($0.54) ($0.46) ($0.68) $1.84 ($0.76) ($0.26) ($1.15) ($0.32)
Weighted Average Basic Shares Outstanding		 26.95M 26.92M 26.98M 27.01M 27.04M 27.03M 39.64M 69.08M 69.20M 61.89M 69.24M
Diluted Earnings per Share		 ($0.60) ($0.60) ($0.68) ($0.54) ($0.46) ($0.68) $1.83 ($0.76) ($0.26) ($1.14) ($0.32)
Weighted Average Diluted Shares Outstanding		 26.95M 26.92M 26.98M 27.01M 27.04M 27.03M 39.93M 69.08M 69.20M 61.89M 69.24M
Weighted Average Basic & Diluted Shares Outstanding		 24.53M 24.55M 24.55M 24.61M 24.65M 46.78M 47.11M 47.13M 47.13M 47.20M 49.45M

Annual Cash Flow Statements for Whitehawk Therapeutics

This table details how cash moves in and out of Whitehawk Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.01 -3.53 19 42 -24 -12 145 -110 24 -34 8.83
Net Cash From Operating Activities		 -0.02 -16 -19 -5.81 -24 -13 -22 -50 -60 -60 -97
Net Cash From Continuing Operating Activities		 -0.02 -16 -19 -5.81 -24 -13 -22 -50 -60 -60 -97
Net Income / (Loss) Continuing Operations		 -0.03 -17 -21 -10 -23 -3.48 -110 -61 -66 -64 -21
Consolidated Net Income / (Loss)		 -0.03 -17 -21 -10 -23 -3.48 -110 -61 -66 -64 -21
Depreciation Expense		 - 0.07 0.05 0.05 0.08 0.01 0.11 0.16 0.17 0.19 0.08
Amortization Expense		 - 0.19 0.08 - - - 0.00 -1.22 -3.14 -1.30 -1.53
Non-Cash Adjustments To Reconcile Net Income		 0.00 0.49 0.89 2.99 1.68 1.27 75 14 12 11 -77
Changes in Operating Assets and Liabilities, net		 0.01 0.52 1.50 1.55 -2.34 -11 12 -1.82 -2.90 -5.54 1.93
Net Cash From Investing Activities		 0.00 -0.11 0.04 -0.04 -0.24 0.00 25 -133 83 25 12
Net Cash From Continuing Investing Activities		 0.00 -0.11 0.04 -0.04 -0.24 0.00 25 -133 83 25 12
Purchase of Property, Plant & Equipment		 - -0.11 -0.01 -0.04 -0.24 0.00 -0.05 -0.44 -3.97 -1.65 -0.55
Purchase of Investments		 - - - - - - 0.00 -145 -64 -36 -149
Divestitures		 - - - - - - - - - 0.00 101
Sale and/or Maturity of Investments		 - - 0.05 - - - 0.00 13 152 63 60
Net Cash From Financing Activities		 0.04 12 37 48 0.00 1.19 142 73 0.33 0.13 94
Net Cash From Continuing Financing Activities		 0.04 12 37 48 0.00 1.19 142 73 0.33 0.13 94
Repayment of Debt		 - -0.26 - - - 1.00 0.00 -0.34 -0.16 -0.02 -0.08
Repurchase of Common Equity		 - - -3.08 -3.50 0.00 - -9.62 -0.32 - 0.00 -5.63
Issuance of Common Equity		 - - 40 52 0.00 0.00 155 73 0.41 0.15 100
Other Financing Activities, net		 - 0.02 0.04 0.08 0.00 0.19 0.83 0.46 0.08 0.00 0.03
Cash Interest Paid		 - - - - - 0.00 0.02 0.23 0.23 0.21 0.00

Quarterly Cash Flow Statements for Whitehawk Therapeutics

This table details how cash moves in and out of Whitehawk Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.64 -5.92 -9.11 -13 -11 -1.87 199 -83 -107 -0.36 -2.78
Net Cash From Operating Activities		 -12 -9.64 -20 -9.16 -16 -15 -12 -53 -15 -17 -22
Net Cash From Continuing Operating Activities		 -12 -9.64 -20 -9.16 -16 -15 -12 -53 -15 -17 -22
Net Income / (Loss) Continuing Operations		 -16 -16 -18 -15 -13 -18 73 -53 -18 -23 -22
Consolidated Net Income / (Loss)		 -16 -16 -18 -15 -13 -18 73 -53 -18 -23 -22
Depreciation Expense		 0.04 0.04 0.05 0.05 0.05 0.05 0.06 0.02 0.01 0.00 0.00
Amortization Expense		 -0.59 -0.49 -0.42 -0.39 -0.31 -0.18 0.02 0.00 -0.72 -0.83 -0.35
Non-Cash Adjustments To Reconcile Net Income		 3.40 2.72 3.76 2.95 2.65 1.42 -86 3.09 2.90 2.39 2.19
Changes in Operating Assets and Liabilities, net		 1.73 4.34 -4.75 2.81 -5.53 1.94 0.73 -3.45 0.19 4.46 -1.86
Net Cash From Investing Activities		 13 3.65 11 -3.57 5.09 13 115 -29 -92 17 19
Net Cash From Continuing Investing Activities		 13 3.65 11 -3.57 5.09 13 115 -29 -92 17 19
Purchase of Property, Plant & Equipment		 -1.10 -0.82 -0.74 -0.54 -0.19 -0.19 -0.55 -0.00 - - 0.00
Purchase of Investments		 -27 -14 -7.65 -19 -9.93 0.00 0.00 -32 -94 -23 -19
Divestitures		 - - 0.00 - - - 101 - -0.07 - 0.00
Sale and/or Maturity of Investments		 41 18 19 16 15 13 15 3.39 2.00 40 39
Net Cash From Financing Activities		 -0.08 0.08 -0.01 0.09 - 0.05 95 -0.85 - 0.03 0.00
Net Cash From Continuing Financing Activities		 -0.08 0.08 -0.01 0.09 - 0.05 95 -0.85 - 0.03 0.00
Repurchase of Common Equity		 - - 0.00 - - - -4.82 -0.80 - - 0.00
Issuance of Common Equity		 - 0.11 0.00 0.09 - 0.05 100 0.02 - 0.03 0.00
Other Financing Activities, net		 0.00 - 0.00 - - - 0.02 0.01 - - 0.00

Annual Balance Sheets for Whitehawk Therapeutics

This table presents Whitehawk Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.02 2.40 21 64 40 19 158 184 132 70 151
Total Current Assets		 0.02 2.23 21 64 40 19 151 180 125 61 149
Cash & Equivalents		 0.02 1.61 20 63 39 4.46 149 39 63 29 38
Short-Term Investments		 - 0.05 - - - - 0.00 134 46 19 108
Prepaid Expenses		 - 0.35 0.31 0.75 0.31 0.08 2.28 3.75 3.83 2.84 3.32
Plant, Property, & Equipment, net		 0.00 0.15 0.11 0.10 0.16 0.02 0.06 0.51 4.80 6.85 0.00
Total Noncurrent Assets		 0.00 0.02 0.02 0.04 0.20 0.12 6.58 3.70 3.04 2.19 1.81
Other Noncurrent Operating Assets		 - 0.02 0.02 0.04 0.20 0.12 2.77 3.70 3.04 2.19 1.81
Total Liabilities & Shareholders' Equity		 0.02 2.40 21 64 40 19 158 184 132 70 151
Total Liabilities		 0.21 15 3.59 5.46 3.40 31 22 26 27 18 15
Total Current Liabilities		 0.21 15 3.59 5.46 3.33 30 15 19 26 17 15
Accounts Payable		 0.00 2.47 3.59 5.46 3.23 17 6.44 3.52 5.90 2.16 0.92
Accrued Expenses		 0.01 - - - - 4.10 8.70 15 14 15 14
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.07 1.20 6.23 7.02 0.83 0.77 0.00
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.19 -86 17 59 37 -12 136 158 105 52 136
Total Preferred & Common Equity		 -0.19 -86 17 59 37 -12 136 158 105 52 136
Preferred Stock		 0.00 - - - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.19 -86 17 59 37 -12 136 158 105 52 136
Common Stock		 0.05 0.00 126 178 179 20 279 362 374 385 489
Retained Earnings		 -0.24 -86 -109 -119 -142 -33 -143 -203 -269 -333 -353
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - 0.00 -0.12 0.03 0.02 0.12

Quarterly Balance Sheets for Whitehawk Therapeutics

This table presents Whitehawk Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 140 111 102 86 234 181 167 127
Total Current Assets		 133 103 93 77 233 179 165 126
Cash & Equivalents		 69 54 41 31 228 145 38 35
Short-Term Investments		 51 34 37 32 3.49 32 125 88
Prepaid Expenses		 4.22 3.43 2.42 2.69 1.55 1.47 2.44 2.51
Plant, Property, & Equipment, net		 3.60 5.69 6.00 5.98 0.03 0.01 0.00 0.00
Total Noncurrent Assets		 3.17 2.81 2.61 2.40 1.36 2.14 1.98 1.68
Other Noncurrent Operating Assets		 3.17 2.81 2.61 2.40 1.36 2.14 1.98 1.68
Total Liabilities & Shareholders' Equity		 140 111 102 86 234 181 167 127
Total Liabilities		 21 21 23 17 12 8.76 9.85 11
Total Current Liabilities		 21 20 22 16 12 8.76 9.85 11
Accounts Payable		 2.61 3.10 2.27 1.37 3.66 3.34 1.63 1.75
Accrued Expenses		 12 11 14 14 8.62 5.42 8.22 9.31
Total Noncurrent Liabilities		 0.95 0.74 0.68 1.02 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 118 90 79 69 222 172 157 116
Total Preferred & Common Equity		 118 90 79 69 222 172 157 116
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 118 90 79 69 222 172 157 116
Common Stock		 371 378 381 383 481 484 487 492
Retained Earnings		 -253 -287 -302 -314 -260 -312 -330 -375
Accumulated Other Comprehensive Income / (Loss)		 -0.02 -0.01 -0.03 0.04 0.00 0.01 0.14 -0.02

Annual Metrics And Ratios for Whitehawk Therapeutics

This table displays calculated financial ratios and metrics derived from Whitehawk Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 5,000,000.00 5,000,000.00 27,070,038.00 40,588,004.00 40,588,004.00 47,111,659.00 20,894,029.00 24,395,117.00 24,525,860.00 24,647,392.00 47,128,362.00
DEI Adjusted Shares Outstanding		 5,000,000.00 5,000,000.00 27,070,038.00 40,588,004.00 40,588,004.00 47,111,659.00 20,894,029.00 24,395,117.00 24,525,860.00 24,647,392.00 47,128,362.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.01 -4.18 -0.83 -0.26 -0.57 -0.09 -5.30 -2.48 -2.68 -2.58 -0.44
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% -92.32% 1,258.57% 60.06% 6.69% -72.50%
EBITDA Growth		 4.03% -70,503.09% -30.32% 47.43% -117.69% 88.88% -3,967.10% 41.81% -17.52% 8.45% 58.76%
EBIT Growth		 4.03% -71,626.10% -29.05% 47.52% -117.46% 88.88% -3,957.44% 42.83% -14.76% 6.22% 60.23%
NOPAT Growth		 4.03% -72,201.07% -28.59% 47.72% -118.62% 89.57% -4,263.16% 43.64% -14.76% 6.22% -69.59%
Net Income Growth		 -2.08% -53,918.80% -26.01% 51.42% -123.83% 85.05% -3,065.32% 45.03% -8.68% 3.15% 67.66%
EPS Growth		 0.00% -245,100.00% 95.80% 69.90% -83.87% -208.77% -605.11% 78.32% 9.29% 3.28% 86.02%
Operating Cash Flow Growth		 -35.67% -72,220.53% -20.14% 69.24% -310.68% 46.75% -76.55% -121.38% -20.19% 0.19% -63.62%
Free Cash Flow Firm Growth		 -68.01% -66,797.00% -39.86% 51.66% -184.27% 115.64% -2,514.91% 41.30% -44.01% 7.84% -16.65%
Invested Capital Growth		 -11.25% -13,688.66% -63.15% -39.55% 49.61% -239.64% -86.25% -12.71% 74.26% 243.59% -279.09%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.01% -100.00% -4.27% 310.92% 38.47% 4.73% 3.64% -50.33%
EBITDA Q/Q Growth		 0.64% -21.78% -16.98% -30.05% 15.26% -32.90% -10.73% -0.91% -2.33% -1.38% -30.49%
EBIT Q/Q Growth		 0.64% -23.72% -16.39% -29.88% 15.19% -31.41% -10.80% 0.82% -3.28% -1.87% -28.27%
NOPAT Q/Q Growth		 0.64% -24.71% -16.21% -29.96% 14.69% -16.97% -10.88% 0.75% -3.22% -1.86% -5.47%
Net Income Q/Q Growth		 -0.57% -26.01% -14.54% -28.15% 14.89% -75.59% -10.04% 3.32% -3.72% -3.25% -31.87%
EPS Q/Q Growth		 0.00% -22.17% 82.54% -255.00% -1.79% -45.45% 1.35% 0.37% -5.17% -3.51% -353.85%
Operating Cash Flow Q/Q Growth		 31.22% -23.97% -9.07% -37.12% 5.24% 11.13% -68.98% 2.20% 2.72% -9.99% -2.29%
Free Cash Flow Firm Q/Q Growth		 39.83% -6.27% -21.46% -29.10% 7.75% 189.52% -10.15% -20.79% 1.07% -4.41% -1.88%
Invested Capital Q/Q Growth		 -120.52% -32,693.38% -93.27% -72.37% -18.75% -5,248.61% -168.12% -2.04% -220.46% -16.13% -72.89%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 0.00% 100.00% 100.00% 91.23% 88.47% 88.36% 89.36%
EBITDA Margin		 0.00% 0.00% 0.00% -55.21% 0.00% -18.47% -9,779.20% -418.88% -307.55% -263.90% -395.73%
Operating Margin		 0.00% 0.00% 0.00% -55.47% 0.00% -17.48% -9,930.09% -411.94% -295.36% -259.62% -1,601.12%
EBIT Margin		 0.00% 0.00% 0.00% -55.44% 0.00% -18.53% -9,788.57% -411.94% -295.37% -259.64% -375.47%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -51.58% 0.00% -23.85% -9,829.46% -397.69% -270.04% -245.13% -288.26%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.06% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 136.66% 102.92% 100.50% 93.04% 95.76% 128.65% 100.42% 96.54% 91.42% 94.41% 76.77%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,935.96% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,914.86% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5,855.18% 0.00%
Return on Equity (ROE)		 18.41% 268.57% -860.37% -27.32% -48.89% -28.86% -177.60% -41.06% -49.90% -80.79% -21.82%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,070.63% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -26.25% 0.00% -9.20% -124.06% -36.64% -45.43% -66.55% -24.26%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -24.42% 0.00% -11.84% -124.58% -35.37% -41.54% -62.83% -18.63%
Return on Common Equity (ROCE)		 18.41% 1,834.88% 11,895.85% -27.32% -48.89% -28.86% -177.60% -41.06% -49.90% -80.79% -21.82%
Return on Equity Simple (ROE_SIMPLE)		 16.86% 19.70% -122.74% -17.72% -63.69% 27.98% -80.71% -38.21% -62.52% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.02 -12 -15 -7.83 -17 -1.78 -78 -44 -50 -47 -80
NOPAT Margin		 0.00% 0.00% 0.00% -38.83% 0.00% -12.24% -6,951.06% -288.36% -206.75% -181.74% -1,120.78%
Net Nonoperating Expense Percent (NNEP)		 9.66% 97.97% -134.81% -6.20% -12.18% -10.31% -44.99% -10.35% -10.95% -21.10% 61.66%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -47.87% -89.98% -58.75%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8.77% 11.53% 11.64% 10.64%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 66.90% 0.00% 14.55% 1,652.77% 264.04% 182.92% 141.43% 417.38%
R&D to Revenue		 0.00% 0.00% 0.00% 88.57% 0.00% 102.94% 1,756.25% 214.66% 200.91% 196.40% 1,273.10%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 155.47% 0.00% 117.48% 10,030.09% 503.17% 383.83% 347.99% 1,690.48%
Earnings before Interest and Taxes (EBIT)		 -0.02 -17 -21 -11 -24 -2.70 -110 -63 -72 -67 -27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.02 -16 -21 -11 -24 -2.69 -110 -64 -75 -69 -28
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 1.18 0.69 0.00 3.70 1.98 0.47 1.48 0.84
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 1.18 0.69 0.00 3.81 1.98 0.47 1.48 0.84
Price to Revenue (P/Rev)		 0.00 0.00 0.00 3.42 0.00 3.17 450.53 20.57 2.03 2.99 15.96
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.82 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.32 0.00 3.56 317.50 9.23 0.00 1.17 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 17.38 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.86 -0.99 0.00 0.00 0.00 -0.81 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 -0.09 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.93 -0.86 -1.92 -1.09 -1.06 -1.36 -1.16 -1.09 -1.07 -0.99 -1.02
Leverage Ratio		 -0.07 -0.19 4.71 1.12 1.09 2.44 1.43 1.16 1.20 1.29 1.17
Compound Leverage Factor		 -0.10 -0.20 4.73 1.04 1.05 3.14 1.43 1.12 1.10 1.21 0.90
Debt to Total Capital		 -604.21% -16,717.93% 0.00% 0.00% 0.00% -440.29% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 -604.21% -16,717.93% 0.00% 0.00% 0.00% -392.39% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -47.89% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -0.04% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% -99,549.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 704.21% 116,366.99% 100.00% 100.00% 100.00% 540.33% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -6.95 -0.76 0.00 0.00 0.00 -3.76 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -6.15 -0.66 0.00 0.00 0.00 -2.11 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.41 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -9.94 -1.06 0.00 0.00 0.00 -5.68 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -8.78 -0.92 0.00 0.00 0.00 -3.18 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.62 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 5.82 -1.44 -1.96 11.56 5.73 -2.47 -6.05 1.96
Noncontrolling Interest Sharing Ratio		 0.00% -583.19% 1,482.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.09 0.15 5.82 11.73 11.87 0.62 9.90 9.56 4.72 3.59 10.26
Quick Ratio		 0.09 0.11 5.64 11.47 11.56 0.62 9.76 9.26 4.33 3.11 10.03
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.01 -9.92 -14 -6.71 -19 2.98 -72 -42 -61 -56 -65
Operating Cash Flow to CapEx		 0.00% -13,873.40% -212,269.95% -15,319.81% -10,066.39% 0.00% -48,745.65% -11,180.18% -1,502.09% -3,600.36% -17,650.91%
Free Cash Flow to Firm to Interest Expense		 -1.76 0.00 0.00 0.00 0.00 3.66 -153.57 -183.82 -263.57 -364.36 0.00
Operating Cash Flow to Interest Expense		 -2.58 0.00 0.00 0.00 0.00 -15.58 -47.81 -215.83 -258.28 -386.69 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -2.58 0.00 0.00 0.00 0.00 -15.58 -47.91 -217.76 -275.48 -397.43 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.47 0.00 0.50 0.01 0.09 0.15 0.26 0.06
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.63 4.56 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.68 0.52 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 196.02 0.00 157.46 28.72 53.86 9.17 4.46 2.09
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.27 0.60 0.75 0.49
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 55.08 80.01 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 538.47 708.39 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,361.30 611.82 486.24 738.64
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,361.30 -18.27 302.16 -738.64
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.01 -1.73 -2.83 -3.95 -1.99 -6.76 -13 -14 -3.65 5.24 -9.39
Invested Capital Turnover		 0.00 0.00 0.00 -5.95 0.00 -3.33 -0.12 -1.14 -2.73 32.66 -3.45
Increase / (Decrease) in Invested Capital		 -0.00 -1.72 -1.09 -1.12 1.96 -4.77 -5.83 -1.60 11 8.89 -15
Enterprise Value (EV)		 0.00 0.00 0.00 6.39 -13 52 356 140 -59 31 -32
Market Capitalization		 0.00 0.00 0.00 69 25 46 505 313 50 78 114
Book Value per Share		 ($0.04) ($17.24) $0.64 $1.45 $0.90 ($0.26) $6.53 $6.49 $4.29 $2.13 $2.89
Tangible Book Value per Share		 ($0.04) ($17.24) $0.64 $1.45 $0.90 ($0.26) $6.35 $6.49 $4.29 $2.13 $2.89
Total Capital		 -0.03 -0.07 17 59 37 -2.30 136 158 105 52 136
Total Debt		 0.16 12 0.00 0.00 0.00 10 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 1.10 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.14 11 -20 -63 -39 5.68 -149 -173 -109 -47 -146
Capital Expenditures (CapEx)		 0.00 0.11 0.01 0.04 0.24 0.00 0.05 0.44 3.97 1.65 0.55
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.05 -1.90 -2.96 -4.09 -2.29 -6.80 -13 -11 -11 -3.02 -11
Debt-free Net Working Capital (DFNWC)		 -0.03 -0.24 17 59 36 -2.34 136 161 98 44 134
Net Working Capital (NWC)		 -0.19 -13 17 59 36 -11 136 161 98 44 134
Net Nonoperating Expense (NNE)		 0.02 5.34 6.43 2.57 6.16 1.69 32 17 15 16 -59
Net Nonoperating Obligations (NNO)		 0.17 11 -20 -63 -39 5.68 -149 -173 -109 -47 -146
Total Depreciation and Amortization (D&A)		 0.00 0.26 0.13 0.05 0.08 0.01 0.11 -1.06 -2.97 -1.11 -1.45
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -20.27% 0.00% -46.63% -1,159.82% -74.70% -43.75% -11.64% -156.80%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 290.35% 0.00% -16.08% 12,142.77% 1,059.37% 403.18% 170.16% 1,882.35%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 290.35% 0.00% -78.00% 12,142.77% 1,059.37% 403.18% 170.16% 1,882.35%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.01) ($0.01) ($1.03) ($0.31) ($0.57) ($0.10) ($12.41) ($2.69) ($2.44) ($2.36) ($0.33)
Adjusted Weighted Average Basic Shares Outstanding		 5M 5M 27.14M 40.59M 40.59M 47.31M 20.93M 22.51M 26.92M 27.03M 61.89M
Adjusted Diluted Earnings per Share		 ($0.01) ($0.01) ($1.03) ($0.31) ($0.57) ($0.10) ($12.41) ($2.69) ($2.44) ($2.36) ($0.33)
Adjusted Weighted Average Diluted Shares Outstanding		 5M 5M 27.14M 40.59M 40.59M 47.31M 20.93M 22.51M 26.92M 27.03M 61.89M
Adjusted Basic & Diluted Earnings per Share		 ($0.01) ($0.01) ($1.03) ($0.31) ($0.57) ($0.10) ($12.41) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5M 5M 21.67M 33.93M 40.59M 42.62M 8.92M 24.44M 24.55M 46.78M 47.20M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.02 -12 -15 -7.83 -16 -1.78 -26 -41 -50 -45 -80
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -38.83% 0.00% -12.24% -2,316.31% -271.23% -206.75% -174.63% -1,120.78%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -51.58% 0.00% -23.84% -9,829.29% -397.69% -270.04% -245.13% -288.26%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -2.73 0.00 0.00 0.00 0.00 -3.32 -233.76 -272.53 -311.40 -438.06 0.00
NOPAT to Interest Expense		 -1.91 0.00 0.00 0.00 0.00 -2.19 -166.00 -190.77 -217.98 -306.63 0.00
EBIT Less CapEx to Interest Expense		 -2.73 0.00 0.00 0.00 0.00 -3.32 -233.86 -274.46 -328.60 -448.81 0.00
NOPAT Less CapEx to Interest Expense		 -1.91 0.00 0.00 0.00 0.00 -2.19 -166.09 -192.70 -235.17 -317.37 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.01% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -14.41% -33.69% 0.00% 0.00% -12.74% -0.53% 0.00% 0.00% -27.31%

Quarterly Metrics And Ratios for Whitehawk Therapeutics

This table displays calculated financial ratios and metrics derived from Whitehawk Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 24,519,860.00 24,525,860.00 24,554,205.00 24,554,205.00 24,614,834.00 24,647,392.00 46,784,618.00 47,109,293.00 47,128,362.00 47,128,362.00 47,196,564.00
DEI Adjusted Shares Outstanding		 24,519,860.00 24,525,860.00 24,554,205.00 24,554,205.00 24,614,834.00 24,647,392.00 46,784,618.00 47,109,293.00 47,128,362.00 47,128,362.00 47,196,564.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.66 -0.66 -0.74 -0.59 -0.51 -0.74 1.56 -1.12 -0.38 -0.49 -0.47
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 40.38% 21.03% -8.76% -0.37% 21.03% 14.43% 33.48% -100.00% -100.00% 0.00% -100.00%
EBITDA Growth		 -21.22% -10.37% -10.55% 21.81% 25.65% -5.13% 463.60% -242.73% -48.49% -34.62% -133.01%
EBIT Growth		 -18.71% -14.80% -15.98% 20.27% 24.85% -6.98% 470.14% -250.28% -46.09% -31.20% -132.57%
NOPAT Growth		 -18.71% -14.50% -15.97% 20.27% 24.85% -6.97% -11.42% -251.32% -45.72% -31.34% -8.20%
Net Income Growth		 -12.63% -16.93% -20.14% 18.85% 23.04% -12.32% 499.23% -260.80% -41.45% -27.24% -130.40%
EPS Growth		 11.76% -25.00% -19.30% 19.40% 23.33% -13.33% 369.12% -40.74% 43.48% -67.65% -117.49%
Operating Cash Flow Growth		 -45.83% 14.73% 7.78% 45.36% -31.26% -56.09% 39.63% -478.32% 1.97% -14.49% -87.19%
Free Cash Flow Firm Growth		 -1,814.36% -148.43% -78.11% 27.78% 33.57% 3.39% 82.43% -125.78% 88.05% 87.39% -412.35%
Invested Capital Growth		 91.81% 74.26% 142.19% 106.43% 648.64% 243.59% -526.40% -2,402.24% -186.88% -279.09% 26.42%
Revenue Q/Q Growth		 -3.92% 6.16% -15.38% 15.43% 16.72% 0.37% -1.30% -100.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 9.69% 1.30% -9.54% 19.92% 14.12% -39.55% 478.84% -175.48% 62.79% -26.51% 7.10%
EBIT Q/Q Growth		 8.69% 0.77% -10.17% 20.13% 13.94% -41.26% 481.15% -175.59% 64.11% -26.87% 5.39%
NOPAT Q/Q Growth		 8.68% 0.76% -10.15% 20.13% 13.93% -41.27% -14.73% -151.84% 64.30% -27.33% 5.48%
Net Income Q/Q Growth		 9.29% 0.20% -12.42% 20.26% 13.97% -45.65% 499.58% -172.06% 66.27% -31.02% 4.55%
EPS Q/Q Growth		 10.45% 0.00% -13.33% 20.59% 14.81% -47.83% 369.12% -141.53% 65.79% -338.46% 71.93%
Operating Cash Flow Q/Q Growth		 28.68% 19.30% -103.78% 53.41% -71.31% 4.04% 21.19% -346.37% 70.96% -12.07% -28.86%
Free Cash Flow Firm Q/Q Growth		 -24.91% 9.20% 8.27% 30.58% -14.90% -32.06% 83.32% -792.21% 93.92% -39.40% -577.60%
Invested Capital Q/Q Growth		 67.18% -220.46% 159.97% -89.81% 2,702.24% -16.13% -278.10% 45.00% -5.75% -72.89% 26.83%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 88.30% 85.35% 87.82% 87.41% 88.85% 89.09% 89.36% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -308.66% -286.97% -371.47% -257.71% -189.63% -263.64% 1,011.91% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -299.53% -280.02% -364.51% -252.21% -185.98% -261.76% -212.99% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -299.53% -279.99% -364.52% -252.24% -186.00% -261.76% 1,010.85% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -273.57% -257.18% -341.66% -236.01% -173.96% -252.42% 1,021.92% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 91.33% 91.85% 93.73% 93.56% 93.53% 96.43% 101.10% 96.38% 90.56% 93.52% 94.35%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -1,277.41% -5,984.87% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -1,273.94% -5,978.45% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 1,239.14% 5,918.13% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -44.14% -49.90% -58.22% -62.26% -38.27% -66.74% 17.69% -8.31% 0.00% -21.82% -68.54%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -2,723.21% -23,836.01% -860.04% -1,070.63% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -41.74% -43.07% -61.69% -47.52% -41.38% -67.09% 162.73% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -38.12% -39.56% -57.82% -44.46% -38.70% -64.70% 164.51% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -44.14% -49.90% -58.22% -62.26% -38.27% -66.74% 17.69% -8.31% 0.00% -21.82% -68.54%
Return on Equity Simple (ROE_SIMPLE)		 -53.65% 0.00% -76.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -12 -14 -11 -9.39 -13 -15 -38 -14 -17 -16
NOPAT Margin		 -209.67% -196.01% -255.15% -176.55% -130.19% -183.23% -212.99% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.52% -2.75% -3.87% -3.44% -3.47% -6.42% 55.26% -11.17% -3.61% -6.04% -3.24%
Return On Investment Capital (ROIC_SIMPLE)		 - -11.79% -15.10% -13.85% -13.63% -25.28% -6.86% -22.27% -8.71% -12.78% -14.17%
Cost of Revenue to Revenue		 11.70% 14.65% 12.18% 12.59% 11.15% 10.91% 10.64% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 188.30% 163.53% 198.39% 127.72% 99.64% 152.66% 179.36% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 199.53% 201.83% 253.93% 211.90% 138.62% 198.19% 123.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 387.83% 365.37% 452.33% 339.62% 274.83% 350.85% 302.35% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -18 -18 -20 -16 -13 -19 72 -55 -20 -25 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -18 -20 -16 -14 -19 72 -55 -20 -26 -24
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.00 0.47 0.64 0.46 0.74 1.48 0.38 0.51 0.57 0.84 1.40
Price to Tangible Book Value (P/TBV)		 1.00 0.47 0.64 0.46 0.74 1.48 0.38 0.51 0.57 0.84 1.40
Price to Revenue (P/Rev)		 5.10 2.03 2.41 1.51 2.02 2.99 3.00 4.08 6.23 15.96 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 3.02 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 33.16% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 5.82 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 1.17 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.05 -1.07 -1.01 -1.02 -0.97 -0.99 -1.02 -1.02 -1.00 -1.02 -1.05
Leverage Ratio		 1.16 1.20 1.19 1.20 1.20 1.29 1.11 1.13 1.12 1.17 1.07
Compound Leverage Factor		 1.06 1.10 1.12 1.13 1.13 1.24 1.12 1.09 1.01 1.10 1.01
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 1.49 -1.12 -1.42 -2.65 -2.69 -3.77 4.78 3.87 3.50 2.01 5.18
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.48 4.72 5.16 4.20 4.89 3.59 18.95 20.41 16.76 10.26 11.36
Quick Ratio		 6.10 4.33 4.69 3.81 4.37 3.11 18.83 20.24 16.51 10.03 11.13
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -25 -23 -21 -15 -17 -22 -3.70 -33 -2.00 -2.79 -19
Operating Cash Flow to CapEx		 -1,088.43% -1,181.86% -2,659.40% -1,692.61% -8,344.15% -8,093.01% -2,153.18% -5,295,700.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -435.42 -402.31 -362.68 -251.76 -441.50 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -206.05 -169.19 -338.84 -157.88 -412.82 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -224.98 -183.51 -351.59 -167.21 -417.76 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.14 0.15 0.17 0.19 0.22 0.26 0.16 0.15 0.11 0.06 0.00
Accounts Receivable Turnover		 5.83 6.63 4.54 4.96 4.09 4.56 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.97 0.68 0.60 0.64 0.70 0.52 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 11.46 9.17 6.03 5.29 5.23 4.46 9.73 7.18 4.81 2.09 0.00
Accounts Payable Turnover		 0.64 0.60 0.61 1.18 1.59 0.75 0.93 0.84 1.03 0.49 0.00
Days Sales Outstanding (DSO)		 62.61 55.08 80.36 73.53 89.23 80.01 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 377.23 538.47 606.20 570.98 524.41 708.39 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 565.98 611.82 597.86 308.53 229.73 486.24 393.44 434.46 354.05 738.64 0.00
Cash Conversion Cycle (CCC)		 -126.14 -18.27 88.71 335.99 383.91 302.16 -393.44 -434.46 -354.05 -738.64 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.14 -3.65 2.19 0.22 6.25 5.24 -9.33 -5.13 -5.43 -9.39 -6.87
Invested Capital Turnover		 -3.09 -2.73 -15.90 -14.67 9.81 32.66 -7.77 -8.80 35.08 -3.45 0.00
Increase / (Decrease) in Invested Capital		 13 11 7.38 3.69 7.39 8.89 -12 -5.36 -12 -15 2.47
Enterprise Value (EV)		 -0.66 -59 -31 -43 -12 31 -148 -89 -73 -32 40
Market Capitalization		 119 50 57 36 51 78 83 88 90 114 163
Book Value per Share		 $4.82 $4.29 $3.68 $3.21 $2.80 $2.13 $4.74 $3.65 $3.33 $2.89 $2.46
Tangible Book Value per Share		 $4.82 $4.29 $3.68 $3.21 $2.80 $2.13 $4.74 $3.65 $3.33 $2.89 $2.46
Total Capital		 118 105 90 79 69 52 222 172 157 136 116
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -119 -109 -88 -79 -63 -47 -231 -177 -163 -146 -123
Capital Expenditures (CapEx)		 1.10 0.82 0.74 0.54 0.19 0.19 0.55 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.97 -11 -5.57 -7.71 -1.12 -3.02 -11 -7.29 -7.41 -11 -8.55
Debt-free Net Working Capital (DFNWC)		 112 98 83 71 62 44 220 170 155 134 114
Net Working Capital (NWC)		 112 98 83 71 62 44 220 170 155 134 114
Net Nonoperating Expense (NNE)		 3.81 3.87 4.63 3.67 3.16 5.01 -88 14 4.06 5.83 5.73
Net Nonoperating Obligations (NNO)		 -119 -109 -88 -79 -63 -47 -231 -177 -163 -146 -123
Total Depreciation and Amortization (D&A)		 -0.54 -0.44 -0.37 -0.34 -0.26 -0.14 0.08 0.02 -0.71 -0.83 -0.35
Debt-free, Cash-free Net Working Capital to Revenue		 -29.96% -43.75% -23.38% -32.37% -4.46% -11.64% -38.60% -33.73% -51.52% -156.80% 0.00%
Debt-free Net Working Capital to Revenue		 483.20% 403.18% 346.89% 297.51% 245.32% 170.16% 793.30% 786.79% 1,078.89% 1,882.35% 0.00%
Net Working Capital to Revenue		 483.20% 403.18% 346.89% 297.51% 245.32% 170.16% 793.30% 786.79% 1,078.89% 1,882.35% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.60) ($0.60) ($0.68) ($0.54) ($0.46) ($0.68) $1.84 ($0.76) ($0.26) ($1.15) ($0.32)
Adjusted Weighted Average Basic Shares Outstanding		 26.95M 26.92M 26.98M 27.01M 27.04M 27.03M 39.64M 69.08M 69.20M 61.89M 69.24M
Adjusted Diluted Earnings per Share		 ($0.60) ($0.60) ($0.68) ($0.54) ($0.46) ($0.68) $1.83 ($0.76) ($0.26) ($1.14) ($0.32)
Adjusted Weighted Average Diluted Shares Outstanding		 26.95M 26.92M 26.98M 27.01M 27.04M 27.03M 39.93M 69.08M 69.20M 61.89M 69.24M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 24.53M 24.55M 24.55M 24.61M 24.65M 46.78M 47.11M 47.13M 47.13M 47.20M 49.45M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -12 -14 -11 -7.54 -13 -11 -38 -14 -17 -16
Normalized NOPAT Margin		 -209.67% -196.01% -255.15% -176.55% -104.58% -183.23% -149.09% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -273.57% -257.18% -341.66% -236.01% -173.96% -252.42% 1,021.92% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -307.74 -310.74 -336.43 -268.72 -353.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -215.42 -217.54 -235.49 -188.08 -247.08 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -326.67 -325.05 -349.17 -278.05 -357.95 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -234.35 -231.86 -248.23 -197.41 -252.03 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 17.46% 0.00% 0.00% -27.31% -0.69%

Financials Breakdown Chart

Key Financial Trends

Whitehawk Therapeutics (NASDAQ: WHWK) remains a development-stage biotech with no product revenue in the most recent quarter, and its financial results continue to be driven by research spending, investment income, and changes in its cash portfolio.

Q1 2026 looked materially weaker on the income statement than the prior year’s first quarter. The company reported $0 in revenue and a net loss of $22.2 million, compared with a profit of $73.0 million in Q1 2025, which was boosted by a large one-time other income gain. Excluding that unusual gain, the business still appears to be operating at a substantial loss.

Cash and investments remain the key story. At March 31, 2026, Whitehawk held $34.8 million in cash and $88.3 million in short-term investments, for total current assets of $125.5 million. Total liabilities were only $11.1 million, leaving the balance sheet lightly levered and liquid for now.

However, the cash balance dropped sharply from the prior quarter. Cash and equivalents fell from $37.9 million in Q3 2025 to $34.8 million in Q1 2026, while short-term investments declined from $124.7 million to $88.3 million. That reflects ongoing operating losses and investment portfolio reshuffling.

Operating cash burn remains significant. In Q1 2026, Whitehawk used $22.2 million in operating cash and reported a net cash decline of $2.8 million after investment activity partially offset the burn. That is a meaningful drain for a company with no revenue.

  • Strong liquidity position: Whitehawk ended Q1 2026 with more than $123 million in cash and short-term investments combined.
  • Low debt burden: Total liabilities were just $11.1 million, giving the company a clean balance sheet.
  • Investment income helps offset losses: Q1 2026 generated $1.3 million in interest and investment income.
  • R&D spending is still supported: The company spent $17.2 million on research and development in Q1 2026, suggesting continued pipeline investment.
  • No revenue yet: Whitehawk reported zero revenue in Q1 2026, so the investment case still depends on clinical and business development progress.
  • Share count rose over time: Weighted average basic shares were 69.2 million in Q1 2026 versus about 39.6 million in Q1 2025, which can dilute future per-share results.
  • Balance sheet is mostly financial assets: Current assets are heavily concentrated in cash and investments rather than operating assets.
  • Persistent operating losses: Whitehawk posted a $23.5 million operating loss in Q1 2026.
  • Cash burn remains high: Operating cash flow was negative $22.2 million in Q1 2026.
  • Investment portfolio is shrinking: Short-term investments fell materially from the prior quarter, reducing the company’s financial cushion.

Looking at the broader trend across the last four years, the most important pattern is volatility. Whitehawk has gone from periods of revenue and unusual large gains to more recent quarters with no revenue and recurring operating losses. The company’s financial health currently looks stable from a balance-sheet perspective, but its earnings and cash flow profile remain highly speculative and dependent on future pipeline progress.

Bottom line: WHWK currently has enough liquidity to fund operations for the near term, but the business is still burning cash with no product revenue. Investors should focus on whether clinical milestones or strategic transactions can eventually convert that balance-sheet strength into a sustainable operating model.

07/13/26 08:30 AM ETAI Generated. May Contain Errors.

Whitehawk Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Whitehawk Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Whitehawk Therapeutics' net income appears to be on an upward trend, with a most recent value of -$20.60 million in 2025, rising from -$31.44 thousand in 2015. The previous period was -$63.69 million in 2024. See Whitehawk Therapeutics' forecast for analyst expectations on what's next for the company.

Whitehawk Therapeutics' total operating income in 2025 was -$114.40 million, based on the following breakdown:
  • Total Gross Profit: $6.39 million
  • Total Operating Expenses: $120.79 million

Over the last 10 years, Whitehawk Therapeutics' total revenue changed from $0.00 in 2015 to $7.15 million in 2025, a change of 714,500,000.0%.

Whitehawk Therapeutics' total liabilities were at $14.52 million at the end of 2025, a 18.6% decrease from 2024, and a 6,982.1% increase since 2015.

In the past 10 years, Whitehawk Therapeutics' cash and equivalents has ranged from $18.53 thousand in 2015 to $148.99 million in 2021, and is currently $37.57 million as of their latest financial filing in 2025.

Over the last 10 years, Whitehawk Therapeutics' book value per share changed from -0.04 in 2015 to 2.89 in 2025, a change of -7,854.2%.


Related Companies

Financial statements for NASDAQ:WHWK last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel